In This Story
BioRegenx Inc. (BRGX0.00%) has submitted its 10-Q filing for the quarterly period ended September 30, 2024.
The filing includes financial statements for the quarter, showing gross sales of $596,510, down from $800,149 in the same quarter the previous year. Net sales were $596,037 after accounting for returns.
Cost of sales for the quarter was $114,389, resulting in a gross profit of $481,648, compared to $571,201 in the previous year.
Operating expenses totaled $808,955, including $562,089 in amortization expense and $236,279 in selling, general and administrative expenses.
The company reported a net loss of $394,860 for the quarter, compared to a net loss of $2,519,035 in the previous year.
For the nine months ended September 30, 2024, gross sales were $2,138,993 with net sales of $1,879,617. The company reported a net loss of $4,653,446 for the period.
Cash used in operating activities for the nine months was $312,787, with cash provided by financing activities amounting to $449,063.
BioRegenx completed a merger with Findit, Inc. on March 8, 2024, resulting in the issuance of 851,977,296 common shares and 3,800 Series A preferred shares.
The company identified material weaknesses in its internal controls over financial reporting, including ineffective control environment and insufficient segregation of duties.
BioRegenx continues to focus on developing and manufacturing medical test equipment and nutritional products, distributed through a direct selling channel.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the BioRegenx Inc. quarterly 10-Q report dated November 14, 2024. To report an error, please email earnings@qz.com.